SalvaRx Group plc Result of AGM (6090M)
July 31 2017 - 8:45AM
UK Regulatory
TIDMSALV
RNS Number : 6090M
SalvaRx Group plc
31 July 2017
SalvaRx Group plc
("SalvaRx" or "the Company")
Result of AGM
SalvaRx (LON: SALV), the drug discovery and development company
focused on cancer immunotherapy, is pleased to announce that at its
Annual General Meeting, which was held earlier today, all
resolutions were duly passed.
For more information on SalvaRx please visit: www.salvarx.io
SalvaRx Group plc
Ian Walters (Chief Executive) Tel: +1 203 441
5451
Northland Capital Partners Limited Tel: +44 (0) 20
Nominated Adviser and Broker 3861 6625
Matthew Johnson / Edward Hutton
(Corporate Finance)
John Howes (Corporate Broking)
Peterhouse Corporate Finance Limited Tel: +44 (0) 20
Joint Broker 7469 0932
Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGRBMTTMBIJBJR
(END) Dow Jones Newswires
July 31, 2017 08:45 ET (12:45 GMT)
Salvarx (LSE:SALV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Salvarx (LSE:SALV)
Historical Stock Chart
From Aug 2023 to Aug 2024